Researchers at Eli Lilly & Co. will use funds from the NIH's Therapeutics for Rare and Neglected Diseases program to develop a long-acting hormone analog to treat hypoparathyroidism. The agency also announced grants for the study of LEOPARD syndrome and retinitis pigmentosa. The grants are intended to remove some financial risk from studying rare diseases and make drug development "more commercially viable and attractive," the NIH said.

Related Summaries